Neuren Set to Benefit as US Extends Rare Pediatric Disease Voucher Program to 2029

Neuren Pharmaceuticals Limited ( (AU:NEU) ) just unveiled an announcement.

Neuren Pharmaceuticals has highlighted the reauthorization by the US Congress of the Rare Pediatric Disease Priority Review Voucher program through 30 September 2029, a move that preserves a lucrative incentive for developers of treatments for rare childhood diseases. Under this program, companies that secure FDA approval for drugs targeting designated rare pediatric conditions receive a voucher for priority review of another drug, which can also be sold to third parties—recently fetching as much as US$200 million. Neuren currently holds Rare Pediatric Disease designations for its pipeline asset NNZ-2591 in Phelan-McDermid, Pitt Hopkins and Angelman syndromes, meaning FDA approval in any one of these indications could yield a voucher that Neuren would own outright, potentially strengthening its financial position and strategic flexibility as it advances its rare disease portfolio.

The most recent analyst rating on (AU:NEU) stock is a Hold with a A$15.50 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.

More about Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on developing new drug therapies for serious neurological and neurodevelopmental disorders that emerge in early childhood and currently have no or limited approved treatment options. Its lead commercial product DAYBUE (trofinetide), including the DAYBUE STIX formulation, is approved by the US FDA for the treatment of Rett syndrome and is licensed globally to Acadia Pharmaceuticals. Neuren’s second key candidate, NNZ-2591, is in clinical development for multiple rare neurodevelopmental disorders, including Phelan-McDermid, Pitt Hopkins and Angelman syndromes, all of which have received orphan drug designation in the US and EU.

Average Trading Volume: 359,394

Technical Sentiment Signal: Hold

Current Market Cap: A$2.06B

See more data about NEU stock on TipRanks’ Stock Analysis page.